Download here the EORTC Progress and Activity Report

EORTC at a glance
Content
FOREWORD............................................................................................................................................... 4
THE CRITICAL ROLE OF NON-COMMERCIAL RESEARCH ...................................... 7
The critical role of non-commercial research in fighting cancers and improving patients’ lives...................... 8
EORTC: A major player in international cancer clinical research................................................................. 10
EORTC: A pioneer in improving patients’ lives............................................................................................ 11
EORTC AT THE HEART.................................................................................................. 15
EORTC: Leading by example....................................................................................................................... 16
1. An international network of world-class expertise.................................................................................... 17
2. Cutting-edge expertise for fast-pace change............................................................................................. 18
3. Unwavering in its principles and values, and compliant with regulations and oversight........................... 19
4. Findings grounded in a large clinical research database of patient information........................................ 20
5. Setting quality standards in research and treatments................................................................................ 22
6. Solution-driven innovation...................................................................................................................... 24
7. Leaving no one behind............................................................................................................................ 26
SHAPING THE FUTURE OF THERAPY........................................................................ 31
Serving the oncology community................................................................................................................ 32
Shaping cancer therapy in partnership......................................................................................................... 34
EORTC funding: an investment with many returns....................................................................................... 40
Annual accounts.......................................................................................................................................... 42
EORTC PEOPLE.............................................................................................................. 45
EORTC Board.............................................................................................................................................. 46
EORTC Research Groups and Task Forces.................................................................................................... 47
Representatives of the top 15 recruiting institutions..................................................................................... 48
EORTC HQ Directors.................................................................................................................................. 49
EORTC HQ Coordination Committee.......................................................................................................... 50
2 | EORTC at a glance
In over 50 years,
190,000 patients trusted EORTC by enrolling in its research.
Each year, thousands more accept to enroll.
This is why.
EORTC at a glance
|3
Foreword
Shaping the Future of Cancer Therapy
Over 50 years ago, visionary
leaders in cancer medicine
realized that advancement of
patient management requires
solid understanding of the
disease and biology, rigorous
testing of novel treatments,
interdisciplinary collaboration,
and exchange beyond state
boundaries.
Oncology has grown from
small sub-disciplines of
internal medicine, radiation
therapy or surgery, respectively,
to a large specialty of its own.
The tremendous increase in
knowledge, understanding,
and treatment has led to organbased specialization. Today,
inter-disciplinary collaboration
and the integration of
pharmacology, molecular
biology, tumor immunology,
and imaging are gaining
increasing importance.
We now understand that there
may be common pathways
leading to tumor proliferation.
the specific molecular
aberrations. Molecular tumor
characterization is becoming a
routine part of daily practice.
Here, multi-stakeholder
programs designed to improve
the development of precision
medicine and establish
foundations for new health
care delivery models will
benefit patients with cancer.
EORTC looks forward
to pursuing its fruitful
collaborations with all cancer
clinical research stakeholders.
Novel treatment strategies
are oriented towards
Roger Stupp
EORTC President
4 | EORTC at a glance
Working Together to Improve Cancer Treatment
cancer clinical research
stakeholders and to provide
support to a network of
experts.
EORTC fulfills a central role as
an international cancer clinical
research infrastructure and is
a unique leader in conducting
non-commercial, academic,
international cancer clinical
studies.
It has a mission to develop,
conduct, coordinate, and
stimulate translational and
clinical research in Europe to
improve the management of
cancer and related problems
by prolonging survival and
improving patient quality
of life. In pursuit of this, we
engage in numerous programs
designed to bring together
EORTC has long recognized
that broad collaboration
is necessary to improve
treatments for patients
with cancer, and these
forms of partnership range
from multidisciplinary
collaborations among our
investigators within clinical
studies, to multi-stakeholder
approaches to cancer drug
development which include
regulators, industry, academia,
patients and payers.
Full clinical, scientific,
operational, quality assurance,
and regulatory support for
clinical studies is provided by
the 180 EORTC Headquarters
staff with strong expertise in
biostatistics, clinical study
design and methodology,
endpoint definition and
analysis, and new initiatives
in imaging and long term
survivorship.
Our SPECTA (Screening
Patients for Efficient Clinical
Trial Access), cancer
survivorship, as well as
other emerging programs are
blooming and complete our
traditional agenda for clinical
studies. These recent additions
to our portfolio provide
EORTC with new opportunities
with further credit and
visibility with partners such as
regulators and payers.
We continue to develop new
forms of multidisciplinary
partnerships which help
optimize cancer clinical
research in Europe and adapt
to the changing landscape.
Today, in a rapidly changing
environment, EORTC is at
the center of clinical research
transformation.
Denis Lacombe
EORTC Director General
EORTC at a glance
|5
THE CRITICAL ROLE OF
NON-COMMERCIAL RESEARCH
The critical role of non-commercial research
in fighting cancers and improving patients’ lives
Despite recent progress, cancer is a still growing burden for
humankind
Cancer figures among the leading causes of morbidity and mortality in Europe and at the global
level.
In 2012, there were an estimated 3.45 million new cancer patients and 1.75 million cancerrelated deaths in Europe1 . Over the next two decades, the global number of new cases is expected
to rise by about 70%, from 14 to 22 million.
At the same time, more than 60% of the world’s total new annual cases occur in Africa, Asia and
Central and South America. These regions account for 70% of the world’s cancer deaths2. This
strong growth in the number of cancer affected patients and the shift towards poorer countries
will, as a consequence, increase inequalities and the economic burden of healthcare, which
developed countries are already facing.
The pivotal role of clinical research
While cancer can be reduced and controlled by implementing strategies for prevention, early
detection and management of patients, investigator-driven clinical research plays a pivotal role in
shaping the future of cancer therapy by:
•
•
•
•
•
Promoting innovative research and rapid access to new agents
Translating laboratory discoveries into practice
Defining state-of-the-art treatment
Identifying ineffective and/or redundant treatments
Guaranteeing best medical practice
8 | EORTC at a glance
In addition, EORTC’s own approach to clinical research ensures:
• Independent objective evaluation
• Multidisciplinary strategies
• Studies on rare cancers
The role of non-commercial research in Europe
In Europe between 2005 and 20133 , all disciplines included, commercial sponsors conducted
61% of all clinical studies, while non-commercial sponsors (among which EORTC) conducted
39% of all clinical studies. It is noteworthy that non-commercial studies are almost exclusively
national in scope, accounting for roughly half of all studies carried out at the national level.
In these respects, EORTC stands out and occupies a unique space among clinical trial sponsors
by harnessing an international network of world-class experts in interdisciplinary collaboration
and exchange beyond state boundaries. As we move into an era of personalized medicine, this
approach is proving to be even more important.
Ferlay et al., EJC 2013;49:1374-1403.
World Health Organization, World Cancer Report 2014, Fact sheet N°297 Updated February 2015.
3
European Medicines Association, Drug Information Association, 23-24 September 2014.
1
2
EORTC at a glance
|9
EORTC: A major player in
international cancer clinical research
EORTC is a private non-profit and independent cancer research organization founded in 1962,
whose mission is to coordinate and conduct international translational and clinical research to
improve the standard of cancer treatment for patients, and ultimately increase survival and quality
of life.
Today EORTC conducts a large share of European non-commercial studies (see chart below) and
has extensive experience in working with many stakeholders across national borders, among
which academic medical centers, research organizations, pharmaceutical companies, regulators
and other healthcare interested parties.
42% of European
non-commercial studies
were conducted by EORTC
between 2005 and 20134
EORTC by the numbers
• 185 employees
• > 190,000 patients in the
databases
• > 23,000 patients in follow-up
• > 200 active studies
• 46 studies open to patient entry
at any time
• 156 ongoing projects
• 21 Groups and Task Forces
• > 4,600 collaborators in 37
countries, in more than 600
institutions
• > 1,900 publications with
EORTC in the titles and/or with
EORTC affiliation
Commercial
Non-commercial
4
European Medicines Association, Drug Information Association, 23-24 September 2014.
10 | EORTC at a glance
EORTC: A pioneer in improving patients’ lives
Patients’ survival and quality of life lies at the heart of EORTC’s approach to research.
Over 50 years since its creation in 1962, EORTC conducted over 1,900 studies, many of which
have resulted in life-changing treatments and the establishment of new standards of care or,
conversely, shown the inefficacy or redundancy of others.
Patient
quality
of life
Radiotherapy
Translational
research
disciplines
Patientdriven
precision
medicine
Designing
strategies that
improve patient
survival and
quality of life
Medical
oncology
Improving
patient
safety
Surgery
Survivorship
& outcome
research
To achieve this, EORTC applies an interdisciplinary methodology, mobilizes a broad network
of clinicians and medical scientists and involves thousands of patients with the clear aim of
improving the standard of cancer treatment through the testing of more effective strategies based
on therapies that are already in use. All of these together, researched and tested alongside each
other, increase knowledge, improve treatments and shape the future of cancer therapy.
EORTC at a glance
| 11
EORTC: a pioneer in Quality of Life research for decades
Patient Reported Outcomes Guidelines stress how
Quality of Life is a critical factor to evaluate in
patients, especially when innovative treatments
are discovered. Here the EORTC plays a leading
role in its capacity as an international leader in
methodological research in measuring Health-
Related Quality of Life in oncology. Quality of
Life results from EORTC Clinical Studies have
had a positive impact on clinical practice in the
treatment of numerous diseases such as brain,
breast, melanoma, lung and ovarian cancer.
The EORTC Quality of Life Core Questionnaire, the QLQ-C30, is one of the most widely used cancer
specific Health Related Quality of Life questionnaires in the world.
It has been translated and linguistically validated into more than 90 languages and extended with over
40 validated modules for specific cancers.
EORTC validated modules are available for:
•
•
•
•
•
•
•
•
•
Bone Metastases
Hepatocellular Carcinoma
Brain
Breast
Lung
Cervical
Multiple Myeloma
Colorectal
Neuroendocrine Carcinoid
12 | EORTC at a glance
•
•
•
•
•
•
•
•
•
Colorectal Liver Metastases
Esophageal
Elderly Cancer Patients
Esophago-Gastric
Endometrial
Ovarian
Gastric
Prostate
Head and Neck
EORTC’s mission statement
EORTC aims to develop, conduct, coordinate, and stimulate
international translational and clinical research
to improve the standard of cancer treatment for patients,
and ultimately increase survival and quality of life.
EORTC at a glance
| 13
EORTC AT THE HEART
EORTC: Leading by example
EORTC’s experience over decades, its interdisciplinary approach, its international network of
world-class expertise and its independence from commercial industries have propelled it to the
forefront of cancer clinical research where it enjoys an internationally acclaimed reputation that
revolves around a number of core features.
EORTC’s equity and core features
7.
No one
left behind
6.
Solution-driven
innovation
5.
Quality
assurance
International
•
Interdisciplinary
•
Multi-tumor
•
Regulatory compliant
•
Independent
4.
Data-driven
analysis
16 | EORTC at a glance
1.
Expert
network
2.
Cutting edge
expertise
3.
Unwavering
independence
and
accountability
1. An international network
of world-class expertise
Extensive and comprehensive studies in the wide field of clinical research are usually beyond the
means of a single hospital or university. It can best be done when medical scientists and clinicians
join forces around the patients’ needs in interdisciplinary and international efforts.
EORTC’s network is the infrastructure of its research model
An unparalleled international network of patients and professionals
• 190,000
patients
• Patients
associations
• 37 countries
Expertise at work in collaboration
• 4,600 scientists
and clinicians
• 640 hospitals
• 100 collaborative
working groups
21 research groups
• Interdisciplinary & multi-tumor
• Over 1,900 studies completed and 200 under way
• 185 staff
EORTC at a glance
| 17
2. Cutting-edge expertise for fast-pace change
EORTC’s research addresses key strategic clinical questions and influences medical practice.
It covers a wide range of cancer disciplines and responds to unmet needs. Its interdisciplinary
approach includes surgery, radiotherapy, medical oncology, pathology, immunology, infectious
diseases, genetics, psychology, health economics…
All of these are complemented by other services in early project optimization, quality of life,
meta-analysis, quality assurance, monitoring, regulatory affairs and pharmacovigilance.
Unique
infrastructure
A interdisciplinary network of investigators and translational scientists
across Europe
Oustanding
track record
A clinical research infrastructure meticulously engineered through peer
reviewed policies and standard operating procedures
Scientific
quality
... guaranteed by world class independent peer review committees
Acclaimed
leadership
in clinical research across disciplines
Integrated
research
Regulatory and
operational skills
Capacity
building
18 | EORTC at a glance
Quality of life
Quality assurance
programs
Rare cancers
in information
technology
Survivorship and
Technical expertise
outcome research
in imaging and
radiotherapy
Molecular screening and
biomarker programs for Specific population:
precision medicine
such as elderly
data management
regulatory and legal
considerations
Education in cancer clinical research methodology and related topics:
courses and conferences; fellowship program
3. Unwavering in its principles and values, and
compliant with regulations and oversight
To maintain its focus on improving patients’ survival and lives, and ensuring robust study results,
EORTC holds firmly to a set of academic, scientific and ethical principles of collaboration and
transparency, while complying with strict oversight procedures.
Principles of independence
Principles on data-sharing
• Peer review process / approval (Protocol
Review Committee)
• Database control by academia
(Independent Data Monitoring
Committee)
• Analysis of primary endpoints
• Publication of primary analysis
• Charters for the use of human biological
material
• Compliance with OECD Principles and
Guidelines for Access to Research Data
from Public Funding
• Release of data once the primary study
results are mature and validated
• Protection of individual patients’ rights to
privacy
Control mechanisms
Action mechanisms
• Quality Assurance Committee (L. Licitra,
Milano, IT)
• Scientific Audit Committee1 (I. Tannock,
Toronto (CA) (until 31 March 2016) E.
Eisenhauer, Kingston (CA) (as of 01 April
2016))
• Institutional Review Board Committee2
(A. Negrouk)
• Membership Committee (M. Grønvold,
Copenhagen (DK))
• Protocol Review Committee3 (F.
Shepherd, Toronto (CA))
• New Drug Advisory Committee4 (JP.
Bizzari, New York (US))
• Translational Research Advisory
Committee5 (S. Tejpar, Leuven (BE))
• Independent data Monitoring Committee6
(M. Mason, Cardiff (UK))
Ensures quality of the science and medicine
Safeguards rights and welfare of patients in clinical studies
3
Ensures academic independence
4
Expedites the introduction of new drugs
5
Ensures relevance and quality of translational research studies
6
Reviews interim analyses of EORTC and intergroup studies for which EORTC is the coordinating group
1
2
EORTC at a glance
| 19
4. Findings grounded in a large clinical research
database of patient information
Since the late 70’s, EORTC’s IT experts have continuously been developing tailored software
solutions that allow for the management of increasingly diverse and complex clinical studies data.
Integrating all sources of data
Radiotherapy
images and data
Diagnostic
and moleculat
imaging data
Biological data
Clinical data
CLINICAL DATA: VISTA TRIALS (Visual Information System for Trials Analysis) is the clinical data
management system developed in-house and used to run all clinical data activities at EORTC
Headquarters. It hosts a suite of applications ranging from:
• Remote Data Capture (RDC)
• Patient Review
• Form Tracker
• Database definition
• Statistical analysis system (SAS) export module
• Online Randomized Trials Access (ORTA) for web-based patient registration and randomization
20 | EORTC at a glance
RADIOTHERAPY IMAGES AND DATA to ensure Radiotherapy Quality Assurance (RTQA).
DIAGNOSTIC AND MOLECULAR IMAGING DATA
• Imaging platform with easy upload portal allows secure and protected transmission of patients’
images:
• Reviewing functionalities powered by VISIO+, a medical image analysis tool
• Collected images stored centrally and linked to patients’ clinical data
• Central review via any internet workstation (does not require software installation)
BIOLOGICAL DATA
• Sample tool for biological data.
• Satellite applications, e.g. regulatory database offering full compliance to regulations.
• PRISMA, EORTC’s clinical trial management system, provides a global overview of all projects
and detailed information about specific protocols (centers, investigators, study milestones,
etc.).
The clinical studies databases are designed by implementing CDISC (Clinical Data Interchange
Standards Consortium) principles.
VISTA Trials was developed on the CDISC operational data model backbone. A web based release
supports CDISC standards from form design through data exports.
All software developed at EORTC Headquarters follows a standard system development life cycle
and complies with United States Food and Drug Administration 21-CFR part 11 (electronic records electronic signature) and EudraLex Volume 4 Annex 11: Computerized Systems.
EORTC at a glance
| 21
5. Setting quality standards
in research and treatments
Quality assurance cannot be compromised and is essential for conducting robust and effective
cancer clinical studies.
Ongoing quality assessment of clinical studies is performed both at EORTC Headquarters and
at investigational sites. EORTC also promotes and encourages quality awareness throughout the
organization and provides expertise in developing and maintaining clinical research of high
quality.
EORTC’s quality assurance aims at:
• Practical quality control to ensure a level of clinical practice that strengthens the scientific
value of the studies
• Standardizing therapeutic practices in participating centers
• Raising the level of medical practice in oncology
Radiotherapy
Medical
oncology
Surgery
Quality
assurance
applied to ...
Medical
imaging
22 | EORTC at a glance
Translational
research
biobanking
and
pathology
• EORTC’s integrated Radiotherapy Quality Assurance (RTQA) helps to develop truly effective
combined treatment modalities. It harmonizes treatment techniques between centers,
standardizes credentialing of modern techniques, enhances compliance with the study
protocol and increases public and regulatory acceptance of drug effect. Working within the
Global Clinical Trials Quality Assurance of Radiation Therapy Harmonization Group, EORTC
seeks to harmonize and improve the quality assurance of radiation therapy implemented
worldwide for the treatment of cancer.
• The SURCARE partnership between EORTC, the European Society of Surgical Oncology,
and the Japanese Clinical Oncology Group seeks to improve the quality of surgery in cancer
clinical studies by developing methods to credential surgical expertise, standardizing surgical
techniques, and centralizing the monitoring of surgical outcomes. The CLIMB project, for
initially unresectable liver metastasis from colorectal cancer, evaluates complications after
surgery, and develops thresholds for quality. The DREAM project seeks to determine the
accuracy of DW-MRI (Diffusion-weighted Magnetic Resonance Imaging Assessment for Liver
Metastasis) in evaluating sites where liver metastases disappear after conversion chemotherapy,
with the goal of using it as an imaging biomarker to guide surgeons in planning treatment of
complex liver metastases.
As of January 2016, 26 international clinical institutions will participate in SURCARE, 400 patients
will enroll in the DREAM trial, 100 post-operative patients will participate in the CLIMB trial and 12
European countries and Japan form the SURCARE network.
• Access to human biological materials, in sufficient quality and quantity and linked to high
quality clinical data is essential to accelerate clinical and translational cancer research. EORTC
studies comply with all applicable ethical, legal and quality assurance requirements regarding
the collection of human biological materials. These are then stored in a validated storage
facility and comply with EORTC’s Human Biological Material Collection, Storage and Use
policy.
• EORTC’s Imaging Platform ensures proper implementation of the different medical imaging
modalities, protocol and imaging guideline compliance, quality control of scans, analysis of
deviations, and process improvements for clinical studies.
4,000 images have been centralized at EORTC’s imaging platform since 2011. 10 studies are under way
with imaging central review to confirm quality and diagnosis, as well as 3 imaging biomarker driven
studies. Real-time scan quality control within 3 working days for 5 ongoing studies.
EORTC at a glance
| 23
6. Solution-driven innovation
EORTC is on a constant look-out for new or better solutions for improving the survival and lives of
patients. It pushes boundaries, step-changes treatments and applies new ideas to old problems.
Today, EORTC is breaking new ground in two areas.
SPECTA
• Screening patients for efficient clinical trial access
• Breaking the silo approach to precision medicine
Exploring drugs and
combinations across a
range of tumors
How the presence of a molecular marker can predict
response to a targeted therapy
SPECTA: First pan-European molecular screening platform acting
across tumor types
Why SPECTA?
The understanding of tumor biology has improved, continues to expand at a rapid pace, and is
opening new opportunities for cancer clinical studies. The identification of molecular alterations
in the cancer, and the possibility to specifically and selectively target them, has dramatically
improved treatment efficacy in cancer patients. SPECTA has embraced this change.
Positioned in Europe as a unique, international, cross tumor, and multidisciplinary clinical
research infrastructure, EORTC stands out with supportive assets that enable it to integrate clinical,
biological, and imaging data with high quality, longitudinally annotated human biological material
collection in a regulatory compliant environment, all guiding principles and pillars at the basis of
the SPECTA Program.
24 | EORTC at a glance
What is SPECTA?
SPECTA is a pan-European network built by EORTC with key institutions collaborating to provide
efficient access for patients to molecularly driven clinical studies.
• To date, the SPECTA platforms for colorectal cancer and thoracic tumors are fully operational,
thus proving that a logistically complex infrastructure to run innovative studies in a
multinational setting is feasible.
• Additional platforms for patients with brain tumors, melanoma, prostate, and rare tumors are
planned to open soon.
EORTC has a collaborative network for reliable and effective development of innovative drugs and
companion diagnostics.
SPECTA: a place to meet for all stakeholders involved in precision medicine
• Collaborative longitudinal clinically annotated biobanks and molecular screening platforms,
shared risk and benefit model between academia, industry and healthcare providers
• Rapid access to patients’ clinico-pathological data and molecular profiles to identify molecular
sub-groups of patients based on biomarker identification and validation
• Efficient access to innovative, biomarker driven, statistically sound basket clinical studies
within the individual platforms and cross-platform umbrella studies targeting specific
molecular alterations for small cohorts of patients
Skillfully Exploring Drugs and Combinations across a Range of
Tumors
EORTC has the flexibility and skills to design, develop and conduct clinical studies based on the
idea that the presence of a molecular marker can predict response to a targeted therapy, and the
study design is independent of tumor histology. With its proven infrastructure, EORTC can support
multiple tumor types and molecular markers.
EORTC trial 90101 CREATE: an EORTC basket trial
CREATE is a phase 2 trial assessing the efficacy of crizotinib in a variety of tumors with specific
alterations leading to ALK and/or MET activation. The trial also includes patients with the same tumor
types without specific ALK or MET alterations in a population comprising 582 patients with the
following diagnoses:
• Anaplastic large cell lymphoma (ALK
alterations)
• Inflammatory myofibroblastic tumor (ALK
alterations)
• Papillary renal cell carcinoma type 1 (MET
alterations)
• Alveolar soft part sarcoma (MET alterations)
• Clear cell sarcoma (MET alterations)
• Alveolar rhabdomyosarcoma (MET and ALK
alterations)
EORTC at a glance
| 25
7. Leaving no one behind
Under the pressures of economic purposes or schools of thought, research can sometimes lose
sight of the patient’s best interests or even of groups of patients altogether. It can also focus on
cancers that affect the largest number of people and forget about rare cancer types. Because it was
created to improve the treatment of all cancer affected patients, EORTC is committed to leaving no
one behind.
Rare tumor
types
Cancer
survivorship
EORTC is
committed to ...
The elderly
26 | EORTC at a glance
Children
Rare Tumor Types
EORTC makes a significant and valuable contribution to rare cancer clinical research:
• By conducting over 50 international clinical studies in a range of rare disease entities such
as: lymphomas, melanoma, leukemia, sarcoma, brain, mesothelioma, penal, vulval, salivary
gland, male breast and anal.
• By participating in the International Rare Cancers Initiative (IRCI), a joint initiative between
EORTC, United States NCI, NIHR Cancer Research Network, and Cancer Research UK
• By bringing together select researchers and organizations for the purpose of developing new
therapies for rare diseases as well as the means to diagnose them. This is witnessed through
its active and leading participation in International Rare Diseases Research Consortium
(IRDiRC), where EORTC Director General Dr. Denis Lacombe serves on the IRDiRC Executive
Committee, and through its participation in several European Commission funded projects in
rare cancers such as EUROSARC, EEC EURO EWING - International Clinical Trials to Improve
Survival from Ewing Sarcoma, and the International Study for Treatment of Childhood Relapsed
acute lymphoblastic leukemia (IntReALL), and is member of Rare Cancers Europe (RCE).
• By tackling rare cancer clinical research through its SPECTArare platform.
EORTC at a glance
| 27
Cancer Survivorship
Survival rates of cancer patients have significantly increased over the past decades. But even
as cancer is controlled in many patients, new problems are becoming increasingly associated
with cancer survivorship. Difficulties such as societal discrimination due to slower performance,
chronic fatigue or partial inability, acceptance for work, education, insurance or credit history are
all things that impact the life of a cancer survivor.
Having successfully completed survivorship activities in breast cancer, lymphoma, testis cancer
and children’s leukemia, EORTC is applying its structured approach to a new set of activities. In
particular, it is actively involved in a European network of organizations and patients cohorts that
addresses the issue of cancer survivorship by quantifying the magnitude of the problem, assessing
its economic burden and formulating evidence-based EU recommendations for rehabilitation of
cancer survivors. This joint effort has proven that it eliminates redundancy and synergizes expertise
and methodology, including data from clinical studies, (population-based) cancer registries,
surveys and social media.
EORTC’s Cancer Survivorship Summits (2014 and 2016) address issues
and topics such as:
• Physical/Medical - pain, fatigue, memory problems, lymphedema, infertility, sexual impairment,
amputations, secondary malignancies, cardiovascular, pulmonary, renal disease, neuro/muscular
impairments
• Psychological - depression, anxiety, uncertainty, isolation, altered body image
• Socio - economic - changes in interpersonal relationships, concerns regarding health or life insurance,
job lock/loss, return to school, financial burden
28 | EORTC at a glance
Cancer in the Elderly
Current challenges in geriatric oncology revolve around the selection of patients for specific
treatments and the delicate balance in prolonging survival while maintaining independence,
functionality and quality of life. Elderly patients have often been shown to receive comparable
benefit from treatments as their younger counterparts and should not be denied access to
treatments based on chronological age alone.
Unfortunately, elderly patients are underrepresented in cancer clinical studies, and it is hard to
form evidence-based clinical recommendations in everyday clinical practice. Here, EORTC is also
shaping the future for the treatment of elderly patients with cancer.
• Elderly patients with HER-2 positive metastatic breast cancer: with very well tolerated new targeted
therapies, EORTC hopes to control tumor growth sufficiently long so that toxic chemotherapy would
not be needed. Many older patients would more likely die from ageing than cancer.
• EORTC-Alliance-SIOG underlines the need for appropriate endpoints and designs for clinical studies
in elderly patients: randomized phase II or even single arm phase II studies in specific subsets of
elderly patients could provide insight in the range of efficacy and toxicity in older populations.
• Describing potential biomarkers to indicate functional biological age of elderly patients with cancer:
studies have shown that slightly more than half of all newly diagnosed cancer cases and more than
two thirds of cancer-related deaths occur in patients 65 years or older. Doctors will increasingly need
to make treatment decisions for older patients, and to make effective decisions, we will need better
biological markers of aging.
• Cancer diagnostic/treatment approaches in nursing homes with the support of Armonea: for older
individuals, EORTC expects to find a conservative, palliative treatment in the majority of cases. This
prospective observational study seeks to open the discussion on this delicate issue starting with a
solid and extensive description of the present situation.
EORTC at a glance
| 29
SHAPING THE FUTURE
OF THERAPY
Serving the oncology community
As a not-for-profit organization focused on improving the patient’s survival and life, EORTC
looks at the oncology community at large not only to draw on its expertise but also to build and
strengthen it.
On an on-going basis, EORTC organizes conferences and events, offers multiple educational
modules, and trains dozens of fellows annually in clinical research. EORTC also believes in
sharing mature and validated data.
Serving
the
oncology
community
Training
fellows
Sharing
data
Events &
education
EORTC events and education 2016
• 2nd EORTC Cancer Survivorship Summit
• Clinical Trial Statistics for nonStatisticians
• Navigating Safely through the Regulatory
Triangle: Clinical Trials – In vitro
Diagnostics – Data Protection
• Innovation and Biomarkers in Cancer
Drug Development (IBCD)
• A One-Day Journey through EORTC
Activities
32 | EORTC at a glance
• 28th EORTC-NCI-AACR Symposium
on Molecular Targets and Cancer
Therapeutics
More information about EORTC
conferences and education available at
www.eortc.org/events
Fellowship
EORTC Fellowship program opens the door to a career in cancer clinical and translational
research.
Established in 1991 to promote European cancer clinical research, EORTC Fellowship Program
encourages physicians, statisticians and scientists from all over the world to train for up to three
years at EORTC Headquarters in Brussels. This program is specifically linked to EORTC Groups,
EORTC research program, or specific research projects undertaken by EORTC Headquarters.
The program provides training in the methodology of clinical research for physicians and other
professionals interested in cancer clinical research, and it is possible to complete a research
project and/or PhD thesis based on data available in EORTC databases. All research work is
performed internationally, and this approach promotes rapid dissemination of clinical trial results.
Financial support for EORTC Fellowship Program is obtained from several sources including
the Vlaamse Liga tegen Kanker, the Dutch Konigin Wilhehmina Fonds Kankerbestrijding, the
Schroeder Foundation, the Melvin Seiden Foundation, Vivaqua, Sally Snowman Survivorship
Initiative and the Pfizer Foundation (within the framework of the PROBE Project). It is coordinated
by EORTC Cancer Research Fund. In addition to support from EORTC, fellowships for medical
doctors are also provided on ongoing basis by the Fonds Cancer / FOCA, Belgium.
From 1991 to 2006: >150 fellows from 36 nationalities; 48 PhD theses.
Data sharing
Access to international data helps produce a better understanding of public health issues and
worldwide disease prevention and control, and EORTC makes data from its clinical studies
available to other academic researchers. As of 2016 EORTC has provided data to 199 ongoing
external projects (96 closed, 103 ongoing).
Considering that on-going research contributing to the completion of datasets must not be
compromised by premature or opportunistic sharing and analysis of data, EORTC only releases
data once the primary study results have been published. Any release of data will take into
consideration individual patients’ rights to privacy.
Investigators who would like to use data from one or more EORTC studies must make a formal
request which is reviewed by EORTC Coordinator for External Research Project. The scientific
merit and feasibility of each request will be evaluated.
EORTC’s policy on data sharing builds on the central principles of the Organization for Economic
Co-operation and Development (OECD) in its report OECD Principles and Guidelines for Access
to Research Data from Public Funding.
EORTC at a glance
| 33
Shaping cancer therapy in partnership
As described previously, EORTC’s research model is built around a network of world-class experts
in hospitals and universities across Europe, and a robust platform of researchers and statisticians
in its headquarter offices in Brussels. But beyond this core infrastructure, EORTC continuously
engages strategically with other stakeholders whose missions, roles and responsibilities have a
direct bearing on cancer clinical research.
EORTC’s partnership framework
Clinical
researchers
Patients
Healthcare
industry
Governments
EORTC
Regulatory
authorities
Payers
European
Commission
34 | EORTC at a glance
Patients: listening to and training the beneficiaries
Working closely with patient organizations brings a critical eye to EORTC activities.
EORTC has close relationships with most patient organizations and cancer leagues across Europe.
They provide EORTC with precious information and feedback on designing information sheets and
informed consent forms, and help in the dissemination of information about progress in EORTC’s
studies.
In turn, EORTC hosts a two-day course designed for patient group leaders with a minimum of
three years’ experience in cancer patient advocacy/patient support/patient information provision.
The objective of this course is to provide high level cancer patient advocates with a stimulating
and challenging training experience leading to a much greater understanding of the entire clinical
studies process. During the course, they also learn about cancer biology, personalized cancer
treatment and care, the organization of clinical research and, importantly, how patient groups can
become closer partners in the design and implementation of clinical studies.
Academic Networks and learned societies: win-win cooperation
The complexity of cancer and the current cancer research landscape increasingly require greater
structured cooperation and partnerships with other learned societies. Due to the emergence of
new academic groups as well as the fragmentation of tumors based on molecular characteristics,
cooperation with other investigator networks is strategically important to ensure rapid patient
recruitment and more effective clinical/translational research.
In a win-win model, learned societies benefit from EORTC’s clinical research expertise while
EORTC can implement complex research programs with the quality assurance required.
EORTC has collaborative projects with national/population based registries. Newly developed
projects not only address the validation of clinical trial outcomes in real life but also improve the
processes for data collection with registries and long term follow-up within joint projects. This
provides a unique setting for addressing issues of big data and data merging challenges which will
help increase our knowledge.
The Healthcare Industry: balancing interests and principles
EORTC successfully conducted studies in partnership with the healthcare industry that eventually
changed practice. the Under the condition that they serve the best interest of all parties and lead to
therapeutic improvements for patients, these studies aim either prospectively or retrospectively at
drug registration.
EORTC at a glance
| 35
However, new forms of partnerships between industry and academia will need to be envisioned
as modern clinical studies require long-term maintenance of technical and cross-validated
infrastructure which is neither in the scope nor in the capacity of industry. New agents can be
best and more rapidly developed if studied in high quality academic environments. Molecular
sub-division of tumor entities imposes the organization of efficient and international networks for
large screening programs for complex studies which cannot be administered outside an optimally
controlled and well-managed infrastructure with the aim of avoiding duplication of screening
efforts by industry.
Complementary commercial and non-commercial agendas need to evolve to ensure the principles
of independence that are so critical for the scientific and patient communities. Both parties need
to address data access policies for shared knowledge and stimulate scientific thinking while new
approaches to Intellectual Property challenges need to be developed. While the integration of
agendas alongside efficient developmental activities and avoiding duplication of effort should be a
cost efficient approach, financial support will remain a major challenge for complex, cutting edge
clinical and translational research.
EORTC has made substantial progress in facilitating interactions with industry for drug
development. Today, the operations to conduct clinical studies and data exchange policies take
into account the interests and needs of the partners. It is critical for both industry and academia,
when partnering on studies which go beyond the single drug development approach, that the
principles of non-commercial independence are respected.
The forms and the methods of cooperation with industry are constantly evolving but are based on
a good balance between academic independence and sets of procedures ensuring full visibility
for industry. EORTC clinical data based are CFR part 11 and CDISC compliant to facilitate
partnerships with industry.
Regulatory Authorities: influencing policy
Constructive dialogue with regulatory bodies is crucial to ensure that, as they are designed, legal
frameworks take into account non-commercial research. In this spirit, EORTC has established and
enjoys open communication with the European Commission and national regulatory agencies. In
particular, EORTC advocates for the need of non-commercial research and of precision medicine,
and about the issues surrounding rare cancers.
36 | EORTC at a glance
In recent months, EORTC engaged in:
• The Finalization of the European Clinical Trial Regulation: In dialogue with the European
Medicines Agency, EORTC takes part in the stakeholder working group regarding the
implementation of the European Clinical Trial Regulation.
• Discussions on the EU Data Protection Regulation: Data privacy is currently one of the most
debated topics within the European Union, and now is the time to take a close look at the topic
from the angle of transparency in clinical studies and, more broadly, in health research. EORTC
actively urges all stakeholders, EU commission, EU parliament and Member States to look at the
data protection regulation from the perspective of individual patient data sharing under the scope
of the clinical trial regulation.
• Discussions on the in vitro Diagnostic Medical Devices Regulation: Treatments in today’s cancer
clinical studies are more targeted. They incorporate technologies that exploit an ever increasing
understanding of cancer biology, and new regulations for these technologies are on the horizon.
Here, EORTC is very involved in making sure that discussions are held to explore the interface
between the Clinical Trial Regulation, expected to be applicable in 2016, and the In Vitro
Diagnostic Medical Devices and Data Protection Regulations now being discussed by the EU
Parliament and Council, and how these three regulations will influence cancer research practice.
• The European Medicine Agency: EORTC sits on the Scientific Advisory Group (SAG) and
contributes to methodological projects in partnership with regulators.
The European Union: Funded Projects
EORTC does not receive core structural support from the European Commission, but it applies to
calls for projects.
Horizon 2020: The H2020 MOTRICOLOR project “MOleculary guided Trials with specific
treatment strategies in patients with advanced newly molecularly defined subtypes of COLORectal
cancer” benefits from EORTC’s proven infrastructure for performing
biomarker-driven phase II clinical studies in this disease.
EIT – Health “InnoLife”: The project Rare Cancer KIC “Establishing a knowledge innovation
community for the societal and market challenge of rare cancer” involves SPECTArare as the
backbone of an international platform involving academia and industry for validating new
technologies usable for research, diagnostic and care of cancer patients.
Innovative Medicines Initiative: By participating in projects such as those put forth by the
Innovative Medicines Initiative, EORTC has become one of Europe’s leading players in
transforming experimental discoveries into new treatments with a significant clinical impact.
EORTC at a glance
| 37
• PHARMATRAIN - with its top class training materials for cancer clinical trial professionals,
EORTC makes a valuable contribution to PharmaTrain which provides accreditation and
professional certification to ensure the competence of medicines development scientists and
clinical investigators.
• QUIC-CONCEPT – aims to provide drug developers with imaging biomarkers that can show
earlier and more accurately how patients’ tumors respond to drugs in cancer clinical studies.
• EUPATI - aims to provide scientifically reliable, objective, comprehensive information to
patients on pharmaceutical research and development and increase the capacity of wellinformed patients to be effective advocates and advisors, for example in clinical studies, with
regulatory authorities and in ethics committees.
• GetReal - aims to inform pharmaceutical R&D and healthcare decision makers how real-world
data and analytical techniques can be used to improve the relevance of knowledge generated
during development, and how this can inform clinical decision making and improve the
efficiency of the R&D process.
38 | EORTC at a glance
Seventh Framework Program
• ECRIN has provided EORTC with the opportunity to upgrade VISTA TRIALS and deploy this
proprietary clinical database management software across Europe.
• Euro-BioImaging - This large scale pan European research infrastructure project has enabled
EORTC to develop the concept for an international imaging support node for international
clinical studies.
• EUROSARC - Clinical studies for rare cancers are a designated strategic need of EORTC.
EUROSARC aims to validate novel local and systemic treatment strategies in localized phase
sarcomas, and innovative targeted therapies in advanced phase sarcomas based on the
scientific understanding of molecular alterations driving the tumors.
• HERMIONE-2MAN - A first in man clinical trial with a first in class bio-therapeutic agent, the
anti-Netrin-1 mAb, which targets a novel signaling pathway and offers potential treatment for a
variety of cancers.
• EEC - EURO EWING Consortium – Aims to improve treatment outcomes for patients with
Ewing sarcoma, a rare cancer. Here two clinical studies will test different chemotherapy
treatments for this rare disease
o EORTC trial 1402 “International Randomized Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumors – Euro Ewing 2012”
o EORTC trial 1403 "International Randomised Controlled Trial of Chemotherapy for the
treatment of Recurrent and Primary Refractory Ewing Sarcoma - rEECur”
EORTC at a glance
| 39
EORTC funding: an investment with many returns
EORTC is very grateful to all of its donors and partners who help it achieve its mission. It wishes to
express its deep appreciation to:
EORTC Cancer Research Fund
Armonea
The Belgian Lottery
Cancer Leagues
Prince Alwaleed Foundation
Sir Ronald Grierson
The Schroder Family Foundation Walgreens Boots Alliance
The Gillings Foundation
NCI USA
Nicolas and Margo Snowman
Ms de Spoelbergh
The European Commission
Fonds Baillet Latour
FOCA (Fonds Cancer)
***
To stay true to its mission of improving treatment for patients and shaping the future of cancer
therapy, EORTC needs to retain full independence over its research. Consequently, it is a not-forprofit organization under Belgian Law and is not subsidized. All of its revenue is composed of
grants from institutional, corporate and private donors, and of fees it charges for studies conducted
in partnership and for services it renders to the oncology community (e.g. events).
In most cases, grants are directed to specific projects, but they also can be invested in EORTC with
the purpose of financing research on rare cancers and therapies with low commercial value but
high impact for patients. Grants of that nature also “move the needle” in the fight against cancers.
***
Supporting EORTC in its mission is the right choice:
• Making a grant directly to EORTC is in essence improving the lives of thousands of patients
and shaping therapy for many more in the future, as EORTC’s track-record shows;
• Investing in EORTC is joining forces with an authoritative and leading partner, whose research
model is unique in its interdisciplinary and multi-tumor approach;
• Selecting EORTC is choosing to tackle the issue and the plight of cancer beyond medical siloes
and national boundaries.
40 | EORTC at a glance
Supporting EORTC in its mission is an investment with many returns:
• Social impact for all donors, through the progress made each year in the treatment of cancer
and the improvement of patients’ lives;
• Corporate social responsibility (CSR) through the tackling of a major global health issue;
• Achieving social objectives for trusts and foundations who seek to invest in effective strategic
partnerships;
• Equity, for those who seek to strengthen brand image among stakeholders (consumers,
shareholders, employees…)
***
The EORTC Cancer Research Fund
Created in 1976, the ECRF collects grants necessary to conduct EORTC’s clinical research
program. This is achieved thanks to the valued contributions of public and private donors.
If you wish to support EORTC research:
Friends of EORTC, for donations from the United Kingdom
• IBAN: GB 30 COUT 1800 0201 8843 95
• SWIFT: COUT GB 22
EORTC Cancer Research Fund, for donations from Belgium
• IBAN: BE79 0682 4292 7433
• BIC: GKCCBEBB
Fondation Française pour la recherche et le traitement du cancer, for donations from France
• IBAN: FR 76 3000 4009 3200 0100 3025 923
• BIC: BNPAFRPPMDT
All donations are subject to /eligible for tax deductibility, subject to /in compliance with
national laws of the countries of origin. EORTC at a glance
| 41
Annual accounts6
Balance sheet 2014 (in Euros)
1. Assets
1.1. Fixed assets
1.1.1. Intangible fixed assets
1.1.2. Tangible fixed assets
1.1.3. Financial fixed assets
1.2. Current assets
1.2.1. Amounts receivable within one year
1.2.2. Current investments
1.2.3. Cash at bank and in hand
1.2.4. Deferred charges and accrued income
2. Liabilities
2.1. Equity
2.1.1. Association or foundation funds
2.1.2. Allocated funds
2.1.3. Accumulated result (+/-)
2.2. Liabilities
2.2.1. Amounts payable within one year
2.2.1.1. Trade debt
2.2.1.2. Advances received on contracts in
progress
2.2.1.3. Taxes, remuneration and social
security
2.2.2. Other amounts payable
2.2.3. Accrued charges and deferred income
42 | EORTC at a glance
93,015,903
292,042
61,237
230,383
422
92,723,861
15,232,838
57,645,684
18,833,015
1,012,324
93,015,903
56,589,246
19,085,702
17,301,808
20,201,736
36,426,657
25,133,792
2,642,665
20,433,713
1,582,398
475,016
11,292,865
Income statement 2014 (in Euros)
1. Operating income
1.1. Turnover
1.2. Other operating income
2. Operating charges
2.1. Services and other goods
2.2. Remuneration, social security costs and pensions
2.3. Depreciation of and amounts written down on formation expenses, on
intangible and tangible fixed assets
2.4. Other operating charges
3. Operating result (+/-)
4. Financial income
5. Financial charges
6. Result on ordinary activities (+/-)
28,580,370
19,478,012
9,102,358
25,843,567
13,081,404
10,011,902
253,565
2,496,696
2,736,803
660,085
117,727
3,279,161
Source: Central Balance Sheet Office at National Bank of Belgium (https://www.nbb.be). EORTC’s accounts for fiscal year 2015 will be
published after their approval by EORTC’s General Assembly of June 2016.
6
EORTC at a glance
| 43
EORTC PEOPLE
EORTC Board
Full members (voting)
Roger Stupp
President
Jean-Yves Blay
Past President
Vincent Grégoire
Vice-President
Patrick Schöffski
Secretary General
Martin van den Bent
Treasurer
Bertrand Tombal
Chair, Clinical
Research Division
Christian Dittrich
Chair,
Translational
Research Division
Malcolm Mason
Chair,
Independent
Data Monitoring
Committee
Mogens Groenvold
Chair, Membership
Committee
Jean-Pierre Bizzari
Chair, New
Drug Advisory
Committee
Frances Shepherd
Chair, Protocol
Review
Committee
Lisa Licitra
Chair, Quality
Assurance
Committee
Sabine Tejpar
Chair,
Translational
Research Advisory
Committee
Ian Tannock,
Chair, SAC
(until 30 june 2016)
Elizabeth Eisenhauer,
Chair, SAC
(as of July 1st, 2016)
Fatima Cardoso
Member
Serge Evrard
Member
Winette
van der Graaf
Member
Denis Lacombe
Director General,
EORTC
Françoise Meunier
Director Special
Projects, EORTC
Alexander Eggermont
Editor-in-Chief,
European Journal of
Cancer
Jean-Claude Horiot
EJC Liaison Officer
46 | EORTC at a glance
Ex-officio members (non-voting)
Diego du Monceau
Chairman, EORTC
Cancer Research
Fund
Victoria Agnew
Director, EORTC
Cancer Research
Fund
EORTC Research Groups and Task Forces
Comprise scientists and/or clinicians organized in two divisions
Clinical Research Division
*
Clinical Research
Division
B. Tombal
Genito-Urinary
Cancers
S. Gillessen
Brain Tumor
M. Weller
Breast Cancer
F. Cardoso
Cancer in
the Elderly
A. Luciani
Cutaneous
Lymphoma
P. Quaglino
Endocrine Tumors
M. Schlumberger
Gastrointestinal
Tract Cancer
M. Ducreux
Gynecological
Cancer
P. Ottevanger
Head and Neck
Cancer
V. Grégoire
Infectious Diseases
P. Donnelly
Leukemia
F. Baron
Lung Cancer
B. Besse
Lymphoma
M. Hutchings
Melanoma
C. Robert
Children’s Leukemia
Y. Benoit
Quality of Life
L. Van De Poll-Franse
Radiation Oncology
W. Budach
Soft Tissue and
Bone Sarcoma
A. Gronchi
Translational Research Division
*
* Chairs of the divisions
Translational Research
Division
C. Dittrich
PathoBiology
J. Martens
Imaging
P. Bourguet
Pharmacology and Molecular
Mechanisms Group
E. Raymond
EORTC at a glance
| 47
Representatives of the top 15 recruiting institutions
U.Z. Leuven, Leuven (BE)
P. Schöffski
Erasmus MC, Rotterdam (NL)
S. Sleijfer
Institut Gustave Roussy, Villejuif (FR)
M. Ducreux
Hôpitaux Universitaires Bordet-Erasme,
Brussels (BE)
A. Awada
CHRU de Lille, Lille (FR)
F. Mazingue
The Christie NHS Foundation Trust,
Manchester (GB)
C. Faivre-Finn
Universitaetsklinikum Heidelberg, Heidelberg
(DE)
M. Platten
Cliniques Universitaires Saint-Luc, Brussels
(BE)
JP. Machiels
48 | EORTC at a glance
Radboud University Medical Center Nijmegen,
Nijmegen (NL)
C. van Herpen
Ospedale Bellaria, Bologna (IT)
A. Brandes
Royal Marsden Hospital, London (GB)
W. van der Graaf
Institut Catala d’Oncologia, L’Hospitalet Hospital Duran i Reynals, Barcelona (ES)
R. Salazar
Centre Hospitalier Universitaire Vaudois,
Lausanne (CH)
D. Wagner
CHU de Lyon, Institut d’Hematologie et
d’Oncologie Pediatrique, Lyon (FR)
Universitair Ziekenhuis Gent, Gent (BE)
Y. Benoit
EORTC HQ Directors
Supports the operational aspects of clinical research implements sound scientific strategy in
concert with the EORTC Groups
Jan Bogaerts, PhD
Methodology Director
Denis Lacombe, MD, MSc
Director General
Vassilis Golfinopoulos, MD, PhD
Medical Director
Jan Bogaerts oversees operational
and
methodological
aspects
associated with the conduct of
EORTC’s international clinical
studies.
Denis Lacombe is involved in the
coordination and administration of all
EORTC activities in order to promote the
EORTC as a major European organization
in Cancer Clinical and Translational
Research. Dr. Lacombe is responsible for
the organization of scientific activities,
public relations, and strategies as defined
by the EORTC Board as well as for internal
and external communications.
Dr.
Vassilis
Golfinopoulos
oversees the development and
implementation of the EORTC’s
scientific strategy and support of
initiatives put forth by the EORTC
Board.
Christian Brunet, MA
Chief Financial Officer
Françoise Meunier, MD, PhD, FRCP
Director of the Special Projects
John Winston
Director of Development
Christian Brunet is head of the
Accounting & Finance and
Contracts & Budget Departments,
and supervises finance-related
processes within EORTC.
Françoise Meunier served as EORTC
Director General from 1991 through 2015.
Now EORTC Director Special Projects, she
is a driving force behind the EORTC cancer
survivorship initiatives and fundraising
projects. Dr. Meunier sits on the EORTC
Cancer Research Fund Board.
John Winston steers international
development and fundraising for
EORTC, raising its profile and
growing its appeal to individual,
corporate
and
foundation
supporters.
EORTC at a glance
| 49
EORTC HQ Coordination Committee
The senior management team of EORTC Headquarters
Denis Lacombe
Director General
Christian Brunet
Chief Financial Officer
Jan Bogaerts
Methodology Director
A. Marinus
Clinical Operations Department
Project Management and CTA Unit
Regulatory Affairs Unit
L. Collette
Statistics & Independent
Data Monitoring Committee
S. Marréaud
Medical &
Pharmacovigilance Unit
Fellowship
P. Ruyskart
IT
Y. Liu
Translational Research,
Radiotherapy & Imaging
C. Gilotay
Data Management
50 | EORTC at a glance
A. Bottomley
Quality of Life
EORTC Past Presidents
JY. Blay, FR (2009-2012)
M. Piccart, BE (2006-2009)
A.M.M. Eggermont, FR (2003-2006)
A.T. van Oosterom, BE (2000-2003)
JC. Horiot, FR (1997-2000)
G. McVie, UK (1994-1997)
E. van der Schueren, BE (1991-1994)
L. Denis, BE (1988-1991)
U. Veronesi, IT (1985-1988)
C. G. Schmidt, DE (1981-1984)
L. G. Latja, UK (1979-1981)
H. Tagnon, BE (1975-1978)
D. W. van Bekkum, NL (1969-1975)
S. Garattini, IT (1965-1968)
G. Mathé, FR (1962-1965)
EORTC at a glance
| 51
Avenue E. Mounier 83/11
1200 Brussels, Belgium
T: +32 2 774 16 11
www.eortc.org • [email protected]